A novel inhibitor of the voltage-gated sodium channel NaV1.7 is being developed as a possible treatment for neuropathic pain.
There is evidence that NaV1.7 mediates pain signaling in human beings, according to Christian Kopfli, CEO of Chromocell Corp.
“The hypothesis is that if you block the pain signals to the brain, you can decrease pain, or in the ideal case, block pain,” he said. “Therefore, we are investigating the molecules that block this ion channel.”
Targeting